These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9721436)

  • 21. Prolongation of concordant xenograft survival by treatment with FTY720.
    Miyata Y; Ohdan H; Noriyuki T; Shintaku S; Shibata S; Yamamoto H; Fan XH; Fudaba Y; Yoshioka S; Asahara T; Fukuda Y; Dohi K
    Transplant Proc; 1998 Dec; 30(8):4163-5. PubMed ID: 9865334
    [No Abstract]   [Full Text] [Related]  

  • 22. The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulation.
    Haghikia A; Gold R
    Am J Pathol; 2010 Jun; 176(6):2599-601. PubMed ID: 20395429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FTY720: early clinical experience.
    Dragun D; Fritsche L; Boehler T; Peters H; Budde K; Neumayer HH
    Transplant Proc; 2004 Mar; 36(2 Suppl):544S-548S. PubMed ID: 15041403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FTY720, a novel immunosuppressant, induces sequestration of circulating lymphocytes by acceleration of lymphocyte homing.
    Chiba K; Yanagawa Y; Kataoka H; Kawaguchi T; Ohtsuki M; Hoshino Y
    Transplant Proc; 1999; 31(1-2):1230-3. PubMed ID: 10083549
    [No Abstract]   [Full Text] [Related]  

  • 25. FTY720 immunomodulation: optimism for improved transplant regimens.
    Ferguson R
    Transplant Proc; 2004 Mar; 36(2 Suppl):549S-553S. PubMed ID: 15041404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FTY720: from bench to bedside.
    Kahan BD
    Transplant Proc; 2004 Mar; 36(2 Suppl):531S-543S. PubMed ID: 15041402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunosuppressive drugs in paediatric liver transplantation.
    van Mourik ID; Kelly DA
    Paediatr Drugs; 2001; 3(1):43-60. PubMed ID: 11220404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Molecular and cellular mechanisms of fingolimod action].
    Nikitin AV
    Antibiot Khimioter; 2013; 58(11-12):38-42. PubMed ID: 24734428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An immunosuppressive regimen using FTY720 combined with cyclosporin in canine kidney transplantation.
    Suzuki S; Kakefuda T; Amemiya H; Chiba K; Hoshino Y; Kawaguchi T; Kataoka H; Rahman F
    Transpl Int; 1998; 11(2):95-101. PubMed ID: 9561675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Future immunosuppressive agents in solid-organ transplantation.
    Gabardi S; Cerio J
    Prog Transplant; 2004 Jun; 14(2):148-56. PubMed ID: 15264459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity.
    Brinkmann V; Lynch KR
    Curr Opin Immunol; 2002 Oct; 14(5):569-75. PubMed ID: 12183155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis].
    Klatt J; Hartung HP; Hohlfeld R
    Nervenarzt; 2007 Oct; 78(10):1200-8. PubMed ID: 17668161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunosuppressive activity of FTY720, sphingosine 1-phosphate receptor agonist: I. Prevention of allograft rejection in rats and dogs by FTY720 and FTY720-phosphate.
    Chiba K; Hoshino Y; Ohtsuki M; Kataoka H; Maeda Y; Matsuyuki H; Sugahara K; Kiuchi M; Hirose R; Adachi K
    Transplant Proc; 2005; 37(1):102-6. PubMed ID: 15808561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel immunosuppressive drug, FTY720, prevents the cancer progression induced by cyclosporine.
    Tanaka T; Takahara S; Hatori M; Suzuki K; Wang J; Ichimaru N; Suzuki S; Morozumi K; Okuyama A; Yamanaka H
    Cancer Lett; 2002 Jul; 181(2):165-71. PubMed ID: 12175531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of sphingosine 1-phosphate signaling in neurologic disease.
    Antel J; Hohlfeld R
    Neurology; 2011 Feb; 76(8 Suppl 3):S1-2. PubMed ID: 21360856
    [No Abstract]   [Full Text] [Related]  

  • 36. FTY720: altered lymphocyte traffic results in allograft protection.
    Brinkmann V; Pinschewer DD; Feng L; Chen S
    Transplantation; 2001 Sep; 72(5):764-9. PubMed ID: 11571432
    [No Abstract]   [Full Text] [Related]  

  • 37. FTY720 in combination with CsA inhibits islet xenograft rejection: a study in the pig-to-rat model.
    Zhang J; Song Z; Wijkström M; Bari S; Sundberg B; Nava S; Groth CG; Korsgren O; Wennberg L
    Transplant Proc; 2000 Aug; 32(5):1017. PubMed ID: 10936327
    [No Abstract]   [Full Text] [Related]  

  • 38. A short-course therapy with FTY720 prolongs allograft survival after canine kidney transplantation.
    Omura T; Suzuki T; Shimamura T; Jin MB; Yokota R; Fukai M; Iida J; Taniguchi M; Magata S; Horiuchi H; Yamashita K; Nomura M; Kishida A; Matsushita M; Furukawa H; Todo S
    Transplant Proc; 1999 Nov; 31(7):2783-4. PubMed ID: 10578289
    [No Abstract]   [Full Text] [Related]  

  • 39. Dose-dependent study of a novel immunosuppressant, FTY720, with the canine renal allograft transplantation model.
    Suzuki T; Shimamura T; Jin MB; Yokota R; Fukai M; Iida J; Taniguchi M; Magata S; Horiuchi H; Yamashita K; Nomura M; Omura T; Kishida A; Furukawa H; Todo S
    Transplant Proc; 1999; 31(1-2):1208-9. PubMed ID: 10083540
    [No Abstract]   [Full Text] [Related]  

  • 40. An effect of FTY720 on acute rejection in canine renal transplantation.
    Yuzawa K; Otsuka M; Taniguchi H; Takada Y; Sakurayama N; Jinzenji Y; Suzuki S; Fukao K
    Transplant Proc; 1998 Jun; 30(4):1046. PubMed ID: 9636422
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.